NDAORALCAPSULEPriority Review
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
8
Data completeness
6/8 — Strong
Priority Review
VONJO (pacritinib) by Akesobio is tyrosine kinase inhibitors [moa]. First approved in 2022.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VONJO (pacritinib) is an oral tyrosine kinase inhibitor approved in February 2022 for myelofibrosis. It works by blocking multiple kinases involved in myeloproliferative disease pathophysiology. The drug represents a targeted small-molecule approach to managing a rare hematologic malignancy.
$93MPart D
Peak3.5 years to LOEVONJO is in peak commercial phase with moderate Part D uptake; the brand team is likely mid-sized with focused commercial execution on specialist channels.
Mechanism of Action
Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Pacritinib Effectiveness in Real-world Settings
Started Aug 2026
60 enrolled
Myelofibrosis (MF)
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Started May 2026
26 enrolled
MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
Started Apr 2026
30 enrolled
Myelofibrosis，MF
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Started Mar 2026
27 enrolled
Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative Neoplasm
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Started May 2025
156 enrolled
VEXASVEXAS Syndrome
Worked on VONJO at Akesobio? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.